Merck KGaA is the latest entrant into the biosimilars market by agreeing to collaborate with India’s Dr. Reddy’s Laboratories to develop and commercialise oncology biosimilars, primarily monoclonal antibodies. The two companies will split R&D costs and Dr. Reddy’s will lead early development through Phase I with Merck taking over further clinical development and manufacturing. Merck will commercialise the biosimilars in approximately 150 countries worldwide and the parties will co-commercialise in the US.